Celltrion Pharm, Inc. (KOSDAQ:068760)

South Korea flag South Korea · Delayed Price · Currency is KRW
68,100
-1,600 (-2.30%)
At close: Feb 6, 2026
32.06%
Market Cap3.02T +22.1%
Revenue (ttm)274.73B +53.2%
Net Income26.03B +146.8%
EPS583.36 +146.0%
Shares Out44.37M
PE Ratio116.74
Forward PEn/a
Dividend200.00 (0.29%)
Ex-Dividend DateDec 29, 2025
Volume168,817
Average Volume255,141
Open68,100
Previous Close69,700
Day's Range66,300 - 69,400
52-Week Range43,627 - 76,200
Beta1.13
RSI54.64
Earnings Daten/a

About Celltrion Pharm

Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. The company offers hepatotonic, anti-inflammatory, antihistamine, respiratory apparatus, circulary system, digestive and stomachic, hormone/metabolic disease, antibiotic/antimycotic, nutrientia and tonic, immunology, oncology, and other drugs. It serves university hospitals and general pharmacies. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju-si, South Korea. Celltrion Pharm, Inc. (KOSDAQ:A068760) operat... [Read more]

Sector Healthcare
Founded 1976
Employees 328
Stock Exchange KOSDAQ
Ticker Symbol 068760
Full Company Profile

Financial Performance

In 2020, Celltrion Pharm's revenue was 233.57 billion, an increase of 34.61% compared to the previous year's 173.51 billion. Earnings were 20.94 billion, an increase of 143.42%.

Financial Statements